Related references
Note: Only part of the references are listed.Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study
Sebastien Miranda et al.
THROMBOSIS RESEARCH (2017)
Treatment of suspected pulmonary embolism in a morbidly obese patient
Viviene Heitlage et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2017)
Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations
Jeremy W. Vandiver et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity
Nathaniel R. Thompson-Moore et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2015)
Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients
Young R. Lee et al.
PHARMACOTHERAPY (2015)
Assessing an enoxaparin dosing protocol in morbidly obese patients
Jeffrey T. Lalama et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2015)
Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review
A. K. Polso et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients
Tzu-Fei Wang et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient
Annika Bickford et al.
AMERICAN JOURNAL OF SURGERY (2013)
Anti-Xa Activity After Enoxaparin Prophylaxis In Hospitalized Patients Weighing Less Than Fifty-Five Kilograms
L. Rojas et al.
THROMBOSIS RESEARCH (2013)
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity
Andrew Freeman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Parenteral Anticoagulants Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
David A. Garcia et al.
CHEST (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gordon H. Guyatt et al.
CHEST (2012)
Implementation of an Enoxaparin Protocol for Venous Thromboembolism Prophylaxis in Obese Surgical Intensive Care Unit Patients
Kyle P. Ludwig et al.
ANNALS OF PHARMACOTHERAPY (2011)
Implications of Obesity for Drug Therapy: Limitations and Challenges
R. Jain et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The effects of obesity on drug pharmacokinetics in humans
Glynn A. Morrish et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series
Eli N. Deal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley et al.
CLINICAL PHARMACOKINETICS (2010)
Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients
Matthew T. Rondina et al.
THROMBOSIS RESEARCH (2010)
Prevention of venous thromboembolism in obesity
Andrew L. Freeman et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2010)
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Edith A. Nutescu et al.
ANNALS OF PHARMACOTHERAPY (2009)
Factors Associated with Bleeding in Elderly Hospitalized Patients Treated with Enoxaparin Sodium A Prospective, Open-Label, Observational Study
Avi Levin et al.
DRUGS & AGING (2009)
Enoxaparin dosing in the elderly using adjusted body weight
Frederick Leri et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2009)
Weight-Based Dosing of Enoxaparin in Obese Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Results from the CRUSADE Initiative
Sarah A. Spinler et al.
PHARMACOTHERAPY (2009)
Cardiovascular risk factors and venous thromboembolism - A meta-analysis
Walter Ageno et al.
CIRCULATION (2008)
Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity
Marilyn J. Borkgren-Okonek et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2008)
Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery
Erin P. Simone et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2008)
Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin
Brea O. Rowan et al.
OBESITY SURGERY (2008)
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism:: findings from a prospective registry (RIETE)
R Barba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Dosage of enoxaparin among obese and renal impairment patients
A Bazinet et al.
THROMBOSIS RESEARCH (2005)
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients
SG Frederiksen et al.
BRITISH JOURNAL OF SURGERY (2003)
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
GJ Sanderink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery
DJ Scholten et al.
OBESITY SURGERY (2002)
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
G Merli et al.
ANNALS OF INTERNAL MEDICINE (2001)
Dosing and monitoring of low-molecular-weight heparins in special populations
BA Duplaga et al.
PHARMACOTHERAPY (2001)
Share Paper
